Public health impact of COVID-19 in French ambulatory patients with at least one risk factor for severe disease.

Millier, Aurélie; Supiot, Romain; Benyounes, Kelly; Machuron, Valérie; Le Lay, Katell; Sivignon, Marine; Leboucher, Claire; Blein, Cécile; Raffi, François

Millier, Aurélie; Supiot, Romain; Benyounes, Kelly; Machuron, Valérie; Le Lay, Katell; Sivignon, Marine; Leboucher, Claire; Blein, Cécile; Raffi, François.

Affiliation

Millier A; HEOR/HTA, Creativ-Ceutical, Paris, France.
Supiot R; HEOR/HTA, Creativ-Ceutical, Paris, France.
Benyounes K; HEOR, Roche SA France, Paris, France.
Machuron V; HEOR, Roche SA France, Paris, France.
Le Lay K; HEOR, Roche SA France, Paris, France.
Sivignon M; HEOR/HTA, Creativ-Ceutical, Paris, France.
Leboucher C; HEOR/HTA, Creativ-Ceutical, Paris, France.
Blein C; HEOR/HTA, Creativ-Ceutical, Paris, France.
Raffi F; Service de Maladies Infectieuses et Tropicales, CHU de Nantes, Nantes, France.

J Mark Access Health Policy ; 10(1): 2082646, 2022.

Article in En | MEDLINE | ID: mdl-35711615

Key words

COVID-19; model; public health impact; simulation

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Language: En Journal: J Mark Access Health Policy Year: 2022 Document type: Article Affiliation country: France Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google